See the latest Vertex Pharmaceuticals Inc stock price (VRTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

A trial of Vertex's suzetrigine in neuropathic back pain met its primary objective, but shares in the company fell as investors reacted to the data.

Review the current valuation for Vertex Pharmaceuticals Inc (VRTX:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880.

View the most recent data and latest information on option chains for Vertex Pharmaceuticals Incorporated Common Stock (VRTX) at Nasdaq.com.